The discovery of maritoclax was exciting because the molecule binds specifically with Mcl-1 and increases the efficacy of ABT-737 in various cancer cells lines [91,110]; however, further pharmacokinetic studies are needed to translate this agent to clinic. This evidence concerns the gene MCL1 and cancer.